Thank you to our Sponsors & Donors
interested in becoming one too?
The work of M4RD relies on the generous contributions of sponsors and donors.
In 2013, Students4RareDiseases (our original name) was grateful to receive funding from Sanofi Genzyme by working with The UK LSD Collaborative. They received the PAL Award for the project “Hear hooves…Think Zebra” and thanks to this award we transformed a small student society into a national organisation. Since then M4RD has received sponsorship and donations from different companies.
Find out more about what M4RD is doing to help make a difference here
We would like to thank all our sponsors and donors for their generous support. Rather than targeting resources on one specific disease they understand that one part of achieving earlier diagnoses is by breaking down the stigma of rare diseases in healthcare. The work of M4RD will benefit all rare diseases.
Find out about the exciting benefits M4RD will provide if you become a Corporate Partner and join us on our journey in driving an attitude change towards rare diseases #daretothinkrare
Please contact Jo McPherson to find out about M4RD’s 2023 work programme and to discuss how you can support M4RD with its mission.
2023 Sponsors
2022 Project-Specific Funding
Thank you to Novartis for sponsoring the M4RD Mystery Monday feature and to the James Tudor Foundation and The Grace Trust for donating towards the further development of M4RD: Learn.
2022
Sponsors
Alexion
Amicus
BioMarin
Bionical Emas
Healx
Kyowa Kirin
Orchard Therapeutics
PTC Therapeutics
Sanofi
SOBI
Donors &
Project specific funding
The Grace Trust
The James Tudor Foundation
The Newby Trust
The Souter Charitable Trust
Chiesi Medical UK
Novartis
Takeda UK
Sponsors
2021
Alexion
Amicus Therapeutics
BioMarin
Bionical Emas
Freeline
Illumina Corporate Foundation
PTC Therapeutics
Sarepta Therapeutics
SOBI
2020
Alexion
Amicus
Sanofi
SOBI
2019
BioMarin
Inventiva
SOBI
2018
BioMarin
Inventiva
SOBI
Ultragenyx
Donors
2021
Takeda
2020
BioMarin
Takeda
Ultragenyx
All funding received is used for achieving the objects of Medics4RareDiseases. M4RD seeks funding from commercial companies with an interest in rare disease including pharmaceutical companies.
The interaction between pharmaceutical companies and patient organisations is regulated by the Association of the British Pharmaceutical Industry’s Code of practice (ABPI Code) in order to protect the public. The ABPI Code of Practice sets out the requirements the industry must comply with and supports companies’ commitment to self-regulation and to operate in a professional, ethical and transparent manner. Medics4RareDiseases is committed to ensuring its activities and partnerships are compliant with the code. Please take time to find out more here.
M4RD does not endorse any companies or products. M4RD is operated independently from these companies and they have no editorial control over M4RD’s content or activities. M4RD’s mission is in raising awareness and any information on this website does not constitute medical advice.